SCHEMBL6035103

SCHEMBL6035103

CCOC(=O)CCc1c[nH]nc1-c1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.47
KDM4E B2RXH2 5/20 0.46
HSD17B10 Q99714 4/20 0.46
HPGD P15428 4/20 0.46
MAPT P10636 4/20 0.46
CYP4F2 P78329 2/20 0.45
CYP4A11 Q02928 2/20 0.45
ALDH1A1 P00352 4/20 0.43
ALOX15 P16050 3/20 0.43
NPSR1 Q6W5P4 3/20 0.43
MAPK1 P28482 2/20 0.43
NPC1 O15118 1/20 0.43
PKM P14618 1/20 0.43
RAB9A P51151 1/20 0.43
GAA P10253 2/20 0.41
PTGS2 P35354 2/20 0.41
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
LMNA P02545 2/20 0.39
KMT2A Q03164 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5371838 0.87 CYP4F2 (0.54) FAAHKDM4EHSD17B10HPGDMAPT
SCHEMBL12844144 0.79 ALDH1A1 (0.38) KDM4EHPGDMAPTALDH1A1NPSR1
Hydrochloric Acid SCHEMBL16986145 0.76 ERBB2 (0.39) KDM4EHPGDMAPTALDH1A1NPSR1
SCHEMBL26129617 0.76 GCGR (0.51) FAAHKDM4EHSD17B10HPGDMAPT
SCHEMBL5387594 0.76 KDM4E (0.52) KDM4EHSD17B10HPGDMAPTALDH1A1
SCHEMBL9117030 0.76 CYP4F2 (0.46) KDM4EHSD17B10MAPTCYP4F2CYP4A11
SCHEMBL6035823 0.75 CYP4F2 (0.50) KDM4EHSD17B10HPGDMAPTCYP4F2
SCHEMBL8259346 0.74 PDE3B (0.48) FAAHKDM4EHSD17B10HPGDMAPT
SCHEMBL5850242 0.74 MAPK14 (0.48) KDM4EHSD17B10HPGDMAPTCYP4F2
SCHEMBL16986189 0.73 ERBB2 (0.36) MAPTALDH1A1MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 FAAH 4023/4885KDM4E 509/4885HSD17B10 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.